Ealixir Stock

Ealixir EBIT Margin

EBIT Margin (Operating Margin) of Ealixir (EAXR) as of Jul 12, 2026.

EBIT Margin

0.00

Last updated:

EBIT Margin (Operating Margin) of Ealixir is 2026 0.00 . EBIT Margin (Operating Margin) of Ealixir was 2025 0.00 . It decreases by % lower compared to the previous year.

For Ealixir, the operating (EBIT) margin of -13.8% is up versus -112.4% a few years ago.

Access this data via the Eulerpool API

Ealixir Stock analysis

What does Ealixir do? Ealixir Inc is a biotechnology company founded in 2012 by Dr. Nithin Rajan. Dr. Rajan earned his doctoral degree in biomedical science from the University of Ottawa and has over ten years of experience in the field of biomedical research. Ealixir Inc is an innovative firm specializing in the development of novel therapeutic technologies based on cell and proteomic research. Ealixir's goal is to help patients with serious or chronic illnesses by offering biological solutions that support the body's natural functions. Ealixir has developed the concept of "lifestyle medicine," aiming to develop treatments that not only combat diseases but also influence the patient's lifestyle to help them lead a healthier life. The company follows an integrative approach, combining the use of medications and other therapeutic approaches. Ealixir specializes in ingredients and technologies that have the potential to stimulate and activate the body to promote natural regenerative processes. One of Ealixir's significant products is the Arthritin system, which is used for the treatment of arthritis and pain. Arthritin utilizes a blend of pain relief, inflammation inhibitors, and regeneration promoters to effectively alleviate arthritis pain and reverse the damage caused by the disease to the joints. Ealixir is also a pioneer in the development of nano "in-minutes" technologies, where nanoparticles are used to actively transport active substances to specific target cells, thereby achieving results in minutes rather than hours. Another important product of Ealixir is Collagenix, a beauty product that uses a blend of collagen, vitamins, and minerals to improve skin structure and wrinkle depth. Ealixir also offers products for animal care and medicine. The company has developed a new product for wound care in pets using the Ealixir technology. The solution consists of antibacterial ingredients and promotes the growth of new tissue. Ealixir also focuses on researching dietary supplements that contribute to overall health and well-being. The company pays special attention to proteins, magnesium, and omega-3 fatty acids. The range includes CBD oil and support for restful sleep. Overall, Ealixir has established itself as a leading company in biomedical research and the development of innovative therapies. The company's products are at the forefront of technology and are developed and tested by a great team of researchers and scientists. The brand has experienced rapid growth in recent years and will undoubtedly achieve many successes in the future, benefiting both patients and animal lovers as well as people who value health and wellness. Ealixir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ealixir stock

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Ealixir since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API

Margins — Ealixir

All Key Metrics — Ealixir